Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 peptide-pulsed dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
WT1 peptide-pulsed dendritic cell vaccine is a cellular immunotherapy developed by the National Cancer Institute (NCI) for the treatment of various hematologic malignancies. The vaccine consists of dendritic cells (DCs), which are potent antigen-presenting cells, that have been loaded (pulsed) with peptides derived from the Wilms' Tumor 1 (WT1) protein. WT1 is a transcription factor that is highly overexpressed in many leukemias and lymphomas but has limited expression in normal tissues, making it an ideal target for cancer vaccines. Once administered, these dendritic cells present the WT1 antigens to the patient's T cells, stimulating a specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing malignant cells. In clinical trials, this vaccine has been evaluated in the post-transplant setting, often in combination with donor lymphocyte infusions (DLI) to enhance the graft-versus-leukemia effect in patients with relapsed or residual disease.
- Other names
- WT1 peptide-loaded allogeneic dendritic cell vaccineWT-1 peptide-loaded allogeneic dendritic cell vaccineWT 1 peptide-loaded allogeneic dendritic cell vaccineWT1-DC vaccineWT-1-DC vaccineWT 1-DC vaccineWT1 peptide-pulsed dendritic cellsWT-1 peptide-pulsed dendritic cellsWT 1 peptide-pulsed dendritic cells
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on WT1 peptide-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 peptide-pulsed dendritic cell vaccine.